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Omalizumab efficacy in cases of 
chronic spontaneous urticaria is not 
explained by the inhibition of sera 
activity in effector cells
Eva Serrano-Candelas1,2, Rubén Martínez-Aranguren3, Olga Vega3, Gabriel Gastaminza3, Joan 
Bartra4, Maria Teresa Audicana5, Jorge M. Núñez-Córdoba6, Jaime Algorta7, Antonio Valero4,8, 
Margarita Martin1,2 & Marta Ferrer  3
Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic 
spontaneous urticaria (CSU). OmAb’s mechanism of action is known to include actions on free IgE 
and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-
autoimmune urticaria where IgE involvement is not clear, suggesting the involvement of additional 
mechanisms of action. In this study, we sought to investigate the ability of OmAb to inhibit mast 
cell and basophil degranulation induced by sera from CSU patients. For this purpose, we performed 
a comparison between the in vitro incubation of sera from CSU patients treated with OmAb and the 
in vivo administration of OmAb in a clinical trial. We found that OmAb added in vitro to sera from 
CSU patients did not modify the ability of the sera to induce cell degranulation. Similarly, the sera 
from patients treated with OmAb in the context of the clinical trial who had a good clinical outcome 
maintained the capacity to activate mast cells and basophils. Thus, we conclude that the beneficial 
activity of OmAb does not correlate with the ability of patient sera to induce cell degranulation.
Omalizumab (OmAb) is a biological drug that specifically recognizes IgE at the same epitope where IgE is bound 
to its high-affinity receptor, FcεRI. In addition to its ability to sequester free IgE, it has been demonstrated that 
OmAb is also capable of accelerating the dissociation of pre-bound IgE in basophils1, 2. Our recent data suggest 
that this also occurs in mast cells and confirm previous basophil data at physiological dose ranges (30–100 µg/
ml, 0.2–0.67 µM) in a time- and dose-dependent manner3. In these conditions, OmAb was able to inhibit early 
IgE-triggered events, such as phosphorylation of PLCγ, LAT and Syk, as well as phosphorylation of ERK and 
later events, such as upregulation of CD63 and leukotriene synthesis3. This result explains the effects of OmAb on 
sustained inflammation in asthmatic patients4.
OmAb has recently been approved for chronic spontaneous urticaria (CSU) and has shown high rates of 
complete control5. CSU is a severely disabling disease6 defined by the spontaneous onset of wheals, with or with-
out angioedema, persisting for ≥6 weeks. Despite its impact on patient quality of life and morbidity, CSU has an 
elusive physiopathology7. It is widely accepted that CSU has an autoimmune component8, wherein dermal mast 
cells and basophils in CSU patients are triggered by circulating IgE against autoantigens9, by IgG against FcεRI10, 11  
or by IgG against IgE itself12, which would be present in the sera of CSU patients. These antibodies may eventually 
activate mast cells and basophils, causing histamine release11 and increased expression of activation markers such 
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as CD6313 or CD203c14. However, the presence of reactive IgE/IgG has not been observed in approximately half of 
CSU patients, and, from a clinical standpoint, autoimmune and non-autoimmune CSU cases are indistinguish-
able from one another. In fact, OmAb is effective in the majority of CSU patients regardless of the presence or 
absence of autoantibodies. Moreover, in some cases, OmAb is able to cause symptom remission in a very short 
timeframe, which cannot be explained by the currently postulated mechanisms of action of OmAb15.
In an attempt to better understand the mechanisms of action of OmAb in CSU and, more importantly, to 
better understand the pathophysiology of this disease, we studied the influence of OmAb on the ability of CSU 
sera to activate mast cells and basophils. Our research was performed in two ways. First, we studied the effects of 
OmAb addition in vitro by pre-incubating sera from CSU patients with OmAb and assessing its ability to mod-
ulate basophil and mast cell activation induced by such sera. Second, we determined whether the ability of sera 
from CSU patients to activate mast cells and primary basophils is altered after OmAb treatment in the context of a 
clinical trial. We also evaluated whether the levels of histamine, tryptase and C-reactive protein in sera from CSU 
patients change during treatment to evaluate their use as potential markers for the efficacy of OmAb treatment.
Results
Sera from CSU patients differentially induce mast and basophil cell degranulation. Thirty-nine 
CSU patients (22 women and 17 men, mean age: 44 ± 12.2 years) with a median disease duration of 6.7 years were 
enrolled in the study. Sera from all patients were collected at the beginning of the study. To determine the activat-
ing capacity of sera from these CSU patients, we assessed its capacity to induce mast cell and basophil degranula-
tion by analyzing CD63 expression on mast cells (LAD2) and basophils of healthy donors by flow cytometry using 
the basophil activation test (BAT)16. Our results revealed that mast cell and basophil sera-dependent degranu-
lation follows the same pattern (Fig. 1) (Pearson’s coefficient 0.730; p-value 8.76 × 10−8). However, the ability of 
sera from CSU patients to induce cell degranulation is very heterogeneous among different sera. Importantly, this 
degree of variability in the cell response to sera activity is not attributable to clinical differences between patients.
Sera from CSU patients incubated with OmAb in vitro do not inhibit cell degranulation. To test 
the ability of OmAb to sequester soluble factors present in CSU or to hinder their activating capacity, we selected 
several CSU sera able to induce cell degranulation of LAD2 cells and basophils and treated them with different 
concentrations of OmAb or human IgG (hIgG) as a control (Fig. 2A). These pre-treated sera were subsequently 
incubated with LAD2 mast cells or primary basophils, and CD63 surface expression was evaluated. Our results 
showed that OmAb does not inhibit the ability of these sera to induce degranulation of LAD2 cells (Fig. 2B) or 
primary basophils (Fig. 2C). To test whether OmAb was fully active (i.e., able to sequester soluble IgE), the same 
OmAb concentrations and procedures were used with IgEB and subsequent triggering with streptavidin (STV), 
achieving a near total inhibition of mast cell degranulation (Fig. 2D,E).
Altogether, our data indicate that OmAb effectively prevents IgE from binding to FcεRI, preventing 
IgE-mediated cell degranulation, but is unable to inhibit CSU patient sera-dependent degranulation in mast cells 
and basophils under the same conditions.
Clinical outcomes from the OmAb clinical trial. Of the 39 CSU patients enrolled in the study 
(Supplementary Table 1), seventeen patients were recruited to participate in a clinical trial to analyze the efficacy 
of OmAb in the treatment of CSU. Fig. 3A shows a brief scheme of the clinical trial design, which was structured 
as a cross-over study. Of these 17 patients (retention rate: 85%), 10 started in the OmAb arm (Arm A) and 7 
started in the placebo arm (Arm B). The mean patient age was 46.7 (SD: 12.5) years, and 9 (52.9%) were women.
The Urticaria Activity Score (UAS) changes from baseline to the end of the study revealed a greater aver-
age improvement in response to OmAb treatment (mean UAS reduction = −2.4, SD = 2.5; median UAS reduc-
tion = −2; p25 = −4, p75 = 0) than in response to placebo (mean UAS reduction = −1.2, SD = 2.6; median UAS 
reduction = −2; p25 = −3, p75 = 1); however, the difference between the placebo and OmAb treatment groups 
was not statistically significant (p = 0.380). In contrast, OmAb treatment resulted in a statistically significant 
improvement in the post-treatment UAS compared with the baseline UAS (baseline UAS: 3; p25 = 2, p75 = 6; 
post-OmAb UAS: 0; p25 = 0, p75 = 2; p = 0.004) (Fig. 3B; Supplementary Table 2A,B).
Comparisons of the change in the chronic urticaria quality of life (CU-Q2OL) score from baseline to the end of 
the study showed a greater average improvement with OmAb treatment (mean overall score reduction = −13.0, 
SD = 22.0; median overall score reduction = −5.4; p25 = −29.3, p75 = 1.1) than with placebo (mean score reduc-
tion = −7.0, SD = 15.0; median overall score reduction = −4.9; p25 = −16.8, p75 = 3.3), although the difference 
was not statistically significant (p = 0.339). OmAb treatment resulted in a statistically significant improvement 
in the post-treatment score compared with the baseline score (baseline overall score: 22.8; p25 = 8.7, p75 = 34.8; 
post-OmAb treatment overall score: 6.5; p25 = 3.3, p75 = 15.2; p = 0.047) (Fig. 3C; Supplementary Table 2A,B).
The comparison between the change in the visual analogue scale (VAS) score from baseline to the end of 
the study showed a greater average improvement with OmAb treatment (mean VAS reduction = −29.8, 
SD = 29.4; median VAS reduction = −23; p25 = −53, p75 = −7) than with placebo (mean VAS reduction = −9.5, 
SD = 41.7; median VAS reduction = −11; p25 = −45, p75 = 21), but the difference was not statistically significant 
(p = 0.218). OmAb resulted in a significantly improved VAS score post-treatment compared with baseline (base-
line VAS: 60; p25 = 25, p75 = 75; post-OmAb VAS: 10; p25 = 1, p75 = 29; p = 0.001) (Fig. 3D; Supplementary 
Table 2A,B).
Sera from CSU patients from the clinical trial maintained its ability to activate mast cells and 
basophils. The results described above indicate that although OmAb treatment showed high efficacy in 
the control of CSU, incubation of sera from CSU patients with OmAb in vitro did not hinder the ability of the 
sera to activate mast cells (LAD2) and basophils. For this reason, we aimed to determine whether the in vivo 
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administration of OmAb had any impact on the activating capacity of patient sera. To test this hypothesis, we 
used sera from CSU patients collected at different time points during the clinical trial: before treatment (untreated 
Figure 1. Sera from CSU patients differentially activate mast cells and basophils. (A) Sera from 39 CSU patients 
were incubated for 30 min with LAD2 cells or ex vivo basophils to evaluate their ability to increase CD63 
expression in the cell membrane. The bar graph represents fold increases of CD63 (mean fluorescence intensity) 
on LAD2 cells (MC; grey bars) and ex vivo basophils (BS; black bars) compared with that on unstimulated cells. 
The vertical dashed line corresponds to a fold change value of 1. The mean CD63 on the cell surface of both cell 
types was correlated (Pearson’s coefficient 0.730; p-value 8.76 × 10−8). Patients enrolled in the clinical trial are 
indicated in the figure.
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Figure 2. Preincubation of sera from CSU patients with OmAb does not modify the ability of the sera to 
stimulate mast cells. (A) Brief scheme of the experimental protocol used in (B and C). (B) LAD2 cells were 
incubated with sera samples from CSU patients who were pre-incubated with different doses of OmAb, or hIgG 
as a control, for 30 min. The bar charts represent the percentage of the mean fluorescence intensity (MFI) of 
CD63 staining relative to that in OmAb/IgG untreated cells (first bar). (C) Basophils from healthy donors were 
incubated with sera samples from CSU patients who were pre-incubated with different doses of OmAb, or hIgG 
as a control, for 30 min. The bar charts represent the percentage of the MFI of CD63 staining relative to that 
in OmAb/IgG untreated cells (first bar). (D) Brief scheme of the experimental protocol used in (E). (E) IgEB 
was incubated with different doses of OmAb, or IgG as a control, for 30 min. Then, LAD2 cells were incubated 
overnight with this mixture, and cells were stained for CD63 after IgEB challenge. The bar charts represent the 
percentage of the MFI of CD63 staining relative to that in OmAb/IgG untreated cells (first bar).
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Figure 3. Clinical trial study. (A) Scheme of the double-blind, placebo-controlled, randomized, cross-over 
(2 × 2) clinical trial. (B) Urticaria activity score (UAS), (C) Chronic Urticaria Quality of Life (CU-Q2oL) score, 
and (D) Visual Activity Scale (VAS) score reported by patients before the start of the study and after the two 
treatment periods (weeks 0, 18 and 40, respectively). The first three bars represent the patients who received 
OmAb followed by placebo (Arm A/A’), and the second three bars represent the patients who received placebo 
followed by OmAb (Arm B/B’). The box plots represent the median, 25th percentile and 75th percentile of UAS/
CU-Q2oL/VAS scores of 17 patients enrolled in the clinical trial before and after receiving OmAb or placebo. 
The outer point corresponds to a patient who did not respond to the OmAb treatment. The Wilcoxon matched-
pairs signed-rank test was used to evaluate differences between the values at baseline and at the end of the study 
(*p < 0.05).
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CSU sera), after the first treatment (corresponding to week 18) and after the second treatment (corresponding to 
week 40).
We incubated these CSU sera samples with LAD2 mast cells and basophils and evaluated their activating 
capacity by measuring CD63 by flow cytometry (Fig. 4A). Our results show that their sera maintained the same 
activating capacity for mast cells (Fig. 4B) and basophils (Fig. 4C) throughout the study. It is important to note 
Figure 4. Sera from CSU patients enrolled in the clinical trial, treated with either OmAb or placebo, did not 
modify the capacity of the sera to activate mast cells or basophils. (A) Protocol followed in the assay. (B) Dot 
plot showing fold change of CD63 mean fluorescence intensity (MFI) of LAD2 mast cells and (C) basophils 
incubated with sera from CSU patients at different time points of the clinical trial.
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that all patients, regardless of the ability of their serum to activate basophils and mast cells, had similar positive 
clinical outcomes with OmAb treatment.
These results show that the capacity of CSU sera to activate mast cells and basophils is not a good marker for 
predicting the clinical response to OmAb treatment.
The histamine, tryptase and C-reactive protein levels present in the sera of CSU patients are 
maintained following OmAb treatment. Because the analysis of the activating capacity of sera from 
CSU patients for mast cells and basophils was not useful for predicting the response to OmAb treatment, we 
sought to determine whether other potential mediators or proinflammatory markers present in the sera changed 
during treatment, as they may serve as markers of symptom remission. We evaluated the levels of histamine, 
tryptase and C-reactive protein in sera from CSU patients during treatment. As shown in Fig. 5, sera from CSU 
patients initially contained variable amounts of these substances, which had no correlation with clinical outcome, 
and the amounts of these soluble factors did not vary throughout the treatment course. Moreover, the concentra-
tions of these markers did not seem to be correlated with each other (Fig. 5D).
Other standard practices reported in the literature include the evaluation of the β-hexosaminidase activity 
of cell supernatants after incubation of CSU sera with mast cells17, 18. Given the results found for histamine, we 
sought to evaluate the β-hexosaminidase content in sera from CSU patients compared with that in sera from 
healthy controls. We found that both sera samples had considerable intrinsic enzymatic activity (Supplementary 
Fig. S1A). Moreover, the evaluation of β-hexosaminidase content in CSU samples during treatment showed no 
change with either OmAb or placebo treatment (Supplementary Fig. S1B). Thus, we concluded that this colori-
metric approach to measuring cell degranulation is not valid to assess sera-dependent mast cell degranulation. 
Moreover, the variability in sera colors, despite subtraction of the background, can also alter the assay results.
Discussion
OmAb has been postulated to be effective in the treatment of CSU due to its ability to sequester free IgE and, 
indirectly, to downregulate FcεRI19–21. Benefits of omalizumab treatment (300 mg) are commonly evident early 
(before week 4) in CSU patients and persisted to week 245, 22, 23. However, in some cases its clinical effectiveness 
is evident much earlier than downregulation of the IgE receptor could take place, given that there are patients 
whose symptoms resolve as early as 24 or 48 h after OmAb administration24, 25. In certain cases, the effectiveness 
of OmAb is thought to be associated with the blocking of autoreactive IgE antibodies9, although the presence of 
these autoantibodies cannot be found in all CSU patients. In a recent review is summarized that OmAb therapy is 
successful in patients with or without a positive test for IgG autoantibodies against FcεRI or IgE, or IgE autoanti-
bodies against thyroperoxidase15. In this study, we aimed to further explore the action of OmAb in CSU patients 
and to better understand the pathophysiology of this disease.
We first explored the capacity of sera from CSU patients to activate mast cells (LAD2) and primary basophils. 
It has been reported that between 5 and 10% of CSU patients present with specific autoantibodies against IgE 
itself12, 26. Using LAD2 cells as a mast cell model permits the uniform evaluation of serum activation in a context 
where FcεRI is not occupied. Therefore, this model allows us to discard anti-IgE antibodies as the soluble factor 
present in the sera responsible for cell degranulation, as LAD2 cells are not IgE-sensitized.
To explore the action of OmAb in CSU patients, we analyzed the ability of OmAb to block the serum-activating 
ability of sera from CSU patients to induce mast cell (LAD2) and basophil degranulation. We used ranges of 
OmAb doses close to physiological concentrations in vitro for comparison with the data obtained from the sera 
from CSU patients treated with OmAb in a clinical trial.
From our in vitro experiments, we can conclude that OmAb did not interfere with or block the serum factor 
or antibody responsible for activating mast cells and basophils. This result highlights the fact that IgE is not the 
activating factor present in the sera from our patients. Consistent with this result, the use of quilizumab, a mono-
clonal antibody that binds to the M1-prime segment of the IgE membrane causing IgE-switch depletion and cell 
apoptosis, did not prove to be effective in a clinical trial involving 45 patients with CSU27.
We next analyzed the efficacy of OmAb in the treatment of CSU in a clinical trial. OmAb treatment was effica-
cious in all CSU subtypes, regardless of their autoimmune and non-autoimmune behavior, defined as the ability 
of the sera to activate basophils and mast cells. Consistent with these findings, it has been recently published that 
serum reactivity can be useful for predicting the time to response to OmAb28. The authors concluded that patients 
with a positive autologous skin serum test (ASST) respond faster to OmAb, but they determined that the final 
OmAb efficacy did not depend on the result of the ASST, which is in accordance with our results demonstrating 
no differences in OmAb effectiveness regardless of the activating capacity of sera from the patients enrolled in the 
clinical trial. This result is in accordance with the clinical experience of others29, 30. Our study shows a statistical 
significant difference between the baseline to OmAb post-treatment. However there is not significant difference 
between placebo and OmAb treatment although we observed a clear improvement. While not statistically sig-
nificant, the magnitude of this improvement may have clinical relevance and should not lead these results to be 
discarded. The residual effect of OmAb in the Arm A/A’ may have contributed to alter significance. In addition, 
the impact of the placebo effect should not be discounted. This symptom reduction in the placebo group has also 
been observed in other OmAb efficacy studies that evaluated the mean change from baseline in symptom scores5.
Our results also reveal that the activating capacity of sera from CSU patients did not change after treatment 
with OmAb. This result is in accordance with that of other studies that did not reveal changes in ASST in CSU 
patients during remission31, 32. In the proof of concept study for the use of OmAb in CSU, Kaplan19 treated 12 CSU 
patients and analyzed the ability of sera to activate basophils before and after administering OmAb. In patients 
with complete resolution of or remitted symptoms, they observed a trend toward the induction of a lower hista-
mine release than that resulting from the same sera at the beginning of the treatment. However, they did not find a 
clear correlation between symptom remission and serum activity, with patients who exhibited complete responses 
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maintaining the same serum activity and vice versa. Moreover, as we will discuss below, the analysis of histamine 
release can yield artificial results due to the serum content of histamine in these patients.
Finally, we also describe the intrinsic levels of the soluble mediators ß-hexosaminidase, histamine, tryptase 
and C-reactive protein in the sera from CSU patients. The concentrations of these soluble factors were not 
observed to be associated with either the clinical outcomes or the responses to treatment. We conclude that the 
use of β-hexosaminidase analysis to determine the ability of patient sera to induce mast cell degranulation could 
Figure 5. Histamine, tryptase or C-reactive protein levels in sera from CSU patients did not change after 
OmAb treatment. The charts represent the concentration of histamine (A), tryptase (B) and C-reactive protein 
(C) in sera from CSU patients at different time points of the OmAb/placebo treatment. (D) Table showing 
Pearson’s coefficients for the different substances tested.
www.nature.com/scientificreports/
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result in artificial values that are determined more by sera activity than by cell activity itself. These results also call 
into question the use of the ASST in the evaluation of autoimmune CSU patients, as soluble factors such brady-
kinin, complement fragments or cytokines may trigger skin mast cell activation and yield false-positive results33.
We should also consider that removal of IgE from the mast cell and basophil surface may desensitize them 
and would leave them unable to be activated by IgE or anti-IgE autoreactive antibodies. However, IgE or anti-IgE 
antibodies are not the unique cause of CSU symptoms and that OmAb is acting through other mechanisms. 
As highlighted by a recent comprehensive review15, there could be alternative mechanisms. Accordingly, it has 
been demonstrated that OmAb is also effective in several types of inducible urticaria, as solar urticaria34, 35, 
cold- and heat-induced urticaria36–38 and delayed pressure urticaria or symptomatic dermographism39, 40 where 
non-IgE-mechanisms have been demonstrated, indicating that OmAb may act beyond IgE-mediated mecha-
nisms. We have recently published a review in which we discuss the action of OmAb cells other than mast cells 
and basophils41. For example, OmAb can target membrane-IgE (mIgE) in IgE+ B-cells, reducing IL4R expression 
and IgE synthesis and decreasing the number of these cells, possibly by causing B-cell anergy42. OmAb has also 
been reported to cause eosinophil apoptosis43, a finding that is in agreement with the decrease in eosinophilia 
found in asthma patients after OmAb administration44. Finally, OmAb has been observed to inhibit corneal angi-
ogenesis in IgE-deficient mice, but it failed to inhibit angiogenesis in Fcgr1−/− mice, suggesting a role of OmAb 
as an IgG45.
In conclusion, our data show that OmAb efficacy in cases of CSU is not explained by the inhibition of sera 
activity in mast cells and basophils and indirectly proves that autoimmunity, understood as the ability of CSU 
sera to activate basophils and mast cells, is not a good biomarker for predicting clinical CSU responses to OmAb 
treatment. We also conclude that proinflammatory components present in sera from CSU patients are not useful 
for predicting OmAb treatment responses. Moreover, these results also suggest a possible direct effect of OmAb, 
not only in mast cells and basophils but also in other cells, which could explain its effectiveness in CSU and other 
pathologies.
Methods
This study was approved by the institutional review board of the University of Navarra. The clinical trial was 
approved by the Spanish Agency of Medicines and Medicinal Products (AEMPS).
Cells and reagents. The LAD2 human mast cell line was provided by Drs A. Kirshenbaum and D.D. Metcalfe 
(National Institutes of Health, Bethesda, MD) and grown in StemPro-34 serum-free medium (Invitrogen Life 
Technologies, Carlsbad, CA, USA) supplemented with StemPro-34 Nutrient, L-glutamine (2 mM), penicillin (100 
U/ml), streptomycin (100 μg/ml), and 100 ng/ml recombinant stem cell factor (SCF) (Amgen, Thousand Oaks, 
CA, USA). The experiments with basophils were performed as previously reported46 using blood from non-atopic 
donors. Biotinylated human IgE (IgEB) was obtained from Abbiotec (San Diego, CA, USA). Streptavidin 
(STV) was purchased from Sigma (Sigma, St. Louis, MO, USA). Whole-molecule human hIgG was obtained 
from Jackson ImmunoResearch (West Grove, PA, USA). PerCP-Cy5.5-conjugated anti-human HLA-DR and 
PE-Cy7-conjugated anti-human CD123 antibodies were purchased from eBioscience (San Diego, CA, USA), and 
APC-conjugated anti-human CD203c and PE-conjugated anti-human CD63 antibodies were purchased from BD 
Bioscience (Mountain View, CA).
CSU patients. Thirty-nine patients were enrolled in this study. All patients had been diagnosed with a 
2-month to 40-year history of CSU, and 31 (79%) suffered from angioedema along with urticaria. Supplementary 
Table 1 in the online supporting information includes demographic and clinical data of these patients. All patients 
provided their written consent to participate in this study, and 17 (43.5%) were included in the clinical trial 
described below.
Ethics statement. The study design and protocol was approved by the Food and Drug Spanish Agency 
(AEMPS), the State Ethics Committee and the Ethics Research Committee of the University of Navarra. The 
authors performed these procedures in accordance with the approved guidelines, obtaining informed consent 
from each subject before conducting the experiments.
Mast cell and basophil activation with sera from CSU patients. LAD2 cells (0.2 × 106) were 
re-suspended in Tyrode’s buffer47 and incubated for 30 minutes at 37 °C with 25 μl of sera from CSU patients in a 
final volume of 60 μl. Cells were collected for CD63 testing using a FACSCalibur flow cytometer (FACScan; BD 
Biosciences). A total of 100 µl of blood from healthy donors was pre-incubated with 20 µl of stimulation buffer 
containing IL-3 at 37 °C for 10 minutes. Thereafter, blood was stimulated with 80 µl of sera. After 30 min at 37 °C, 
stimulation was stopped and the serum was eliminated by washing the samples with cold washing buffer (PBS, 
2 mM EDTA). Samples were stained with HLA-DR, PerCP-Cy5.5, CD123 PE-Cy7, CD203c APC and CD63 PE 
for 30 min at 4 °C. Erythrocytes were lysed for 15 min at RT, and samples were washed twice prior to separating 
them in a FASCCanto II flow cytometer (FACScan). Data were analyzed with FlowJo Tree Star software (Ashland, 
OR, USA). In all cases, dead cells were eliminated based on their forward (FSC) and side scattering (SSC) profiles.
In vitro preincubation of sera from CSU patients or IgE with OmAb/IgG and LAD2 and primary 
basophil stimulation. Sera from CSU patients were treated for 30 min at 37 °C with OmAb or hIgG, as an 
immunoglobulin control, at different concentrations in Tyrode’s buffer. Then, LAD2 cells and basophils from 
donors were stimulated with these pre-treated sera as described above, and CD63 was assessed by flow cytometry. 
For IgE-dependent LAD2 degranulation, biotinylated IgE (IgEB) was incubated with different concentrations of 
OmAb/hIgG for 30 min at 37 °C. Then, LAD2 mast cells were incubated overnight with this mixture at 37 °C, and, 
after extensive washing, cells were stimulated with streptavidin for 30 min. CD63 was assessed by flow cytometry.
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Clinical trial. The multicenter, double-blinded, placebo-controlled, randomized, cross-over clinical trial 
of OmAb was registered at Clinical Trials.gov (NCT01713725). Twenty participants were recruited from those 
included in the study. These patients were randomly assigned to receive OmAb or a matching placebo for a total 
of 14 weeks (first period). A total of 300 mg of OmAb was subcutaneously administered every two weeks during 
the first four weeks and every 4 weeks thereafter. After a washout period of 4 weeks, patients were crossed over to 
the other treatment for an additional 14 weeks (second period). Patients were followed-up for 12 weeks after the 
end of the second period.
Disease activity and quality of life assessment. The urticaria activity score (UAS) was used to evaluate 
the main CSU characteristics (pruritus and number of wheals), with a total daily score ranging from 0 to 6 (lowest 
to highest disease activity)48. The validated Spanish version of the Chronic Urticaria Quality of Life Questionnaire 
(CU-Q2OL) was used to measure 6 CSU-specific dimensions of health-related quality of life: pruritus (2 items), 
impact on life activities (6 items), sleep disorders (5 items), limitations (3 items), appearance (5 items), and swell-
ing (2 items)49. Scores were transformed to a 0 to 100 scale, with higher scores representing a worse quality of 
life. Additionally, the visual analogue scale (VAS) was used as a complementary measure of CSU severity. The 
VAS score was determined by measuring the distance in millimeters (mm) between the left corner of a straight, 
100-mm horizontal line and the mark indicated on the line by each patient.
LAD2 and primary basophil stimulation with sera from CSU patients treated with OmAb/
Placebo. Patient sera samples from the clinical trial phases were obtained at the start of the study, after admin-
istering 5 OmAb or placebo doses (week 18) and at the end of the study (week 40). These sera samples were used 
to assess cell degranulation of mast cells and basophils as detailed above.
Measurement of soluble substances in sera from CSU patients. Histamine, tryptase and C-reactive 
protein levels in sera were measured using the EIA Histamine kit (Immunotech, BeckmanCoulter, Marseille, 
France), the enzyme immunoassay ImmunoCAP FEIA (Thermo Fisher, Uppsala, Sweden) and the C-reactive 
protein High Sensitivity immunoturbidimetric assay (Roche Diagnostics, Mannheim, Germany), respectively, 
following the manufacturers’ instructions. Measurement of intrinsic β-hexosaminidase from CSU sera was per-
formed by incubating sera with substrate (p-nitrophenyl-N-acetyl-β-D-glucopyranoside) for 30 min and, after 
stopping the reaction, measuring the absorbance at 405 nm.
Statistical data analysis. The results of the in vitro assays are expressed as the means ± standard devi-
ations of the mean value (SD). One-way ANOVA or unpaired t-tests were used to determine significant dif-
ferences (p-value), and Pearson’s coefficient was used to analyze the correlation between different parameters 
using GraphPad software. The Wilcoxon matched-pairs signed-rank test was used to compare efficacy parameters 
according to interventions using Stata 14 (StataCorp LP, College Station, TX). Asterisks indicate the following p 
values: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.
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